Millennium Management’s China SXT Pharmaceuticals SXTC Stock Holding History

Millennium Management’s Portfolio SXTC Stock Details SXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2	Closed	-$37K	–	6841
2022 Q4	$37K	Hold	2	–	–	﹤0.01%	5877
2022 Q3	$35K	Buy	+2	New	+$87.2K	﹤0.01%	6297
2022 Q2	–	Hold	0	–	-$3K	–	7480
2022 Q1	–	Hold	0	–	–	–	6813

Other funds holding SXTC

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Millennium Management's SXTC Position: Q1 2023 in Review

Millennium Management sold out of China SXT Pharmaceuticals (SXTC) in Q1 2023, closing a stake of 2 shares — an estimated $37K sold.

Millennium Management first reported a position in SXTC in Q3 2022 and held it in 2 quarters. The position peaked at $37K in Q4 2022. 6 funds tracked by Wall St. Rank hold SXTC as of Q1 2023.

Millennium Management reported no remaining China SXT Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Millennium Management sold 2 China SXT Pharmaceuticals shares in Q1 2023, an estimated $37K.
Millennium Management first reported a position in China SXT Pharmaceuticals in Q3 2022 and held it in 2 quarters.
Millennium Management's China SXT Pharmaceuticals position peaked at $37K in Q4 2022.
6 funds tracked by Wall St. Rank held China SXT Pharmaceuticals as of Q1 2023.

Based on Millennium Management's 13F filing for Q1 2023, filed 15 May 2023.